Trial Profile
Adherence and persistence to Rivaroxaban, Dabigatran, and vitamin K antagonist in patients with atrial fibrillation for stroke risk reduction
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2017
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Dabigatran etexilate
- Indications Stroke
- Focus Therapeutic Use
- 06 Sep 2017 New trial record